Detalles de la búsqueda
1.
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
Br J Dermatol
; 184(6): 1047-1058, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32880909
2.
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Br J Dermatol
; 182(6): 1348-1358, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31887225
3.
Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).
J Eur Acad Dermatol Venereol
; 33(2): 325-332, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30317671
4.
Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab.
J Eur Acad Dermatol Venereol
; 33(3): 568-576, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30325534
Resultados
1 -
4
de 4
1
Próxima >
>>